Are Peptides Legal in North Carolina? (2026)

By the Peptide Bureau Research Team Regulation Reviewed by the Peptide Bureau Research Team on 28 September 2026

Not legal advice. This page summarises public statutes, board statements and enforcement records for North Carolina as of 28 September 2026, for general information. It is not a legal opinion. Laws change; check the linked sources or a licensed North Carolina attorney before relying on anything here. Compounds are discussed in a research context only.

Short answer. There is no North Carolina statute that bans buying or possessing research peptides as a category. Federal law does the regulating: selling an unapproved peptide for human use is a federal violation by the seller, and human growth hormone has its own federal statute. North Carolina does go further on at least one compound: Chorionic gonadotropin (hCG), Schedule III (details below). The North Carolina Board of Pharmacy has taken a position on compounded semaglutide or tirzepatide, which matters if you are looking at a clinic or telehealth prescription rather than a research vial. Verified against the sources listed at the bottom on 28 September 2026. Not legal advice.

North Carolina at a glance

State controlled-substances law: North Carolina Controlled Substances Act, N.C. Gen. Stat. Chapter 90, Article 5, Sections 90-86 et seq.; schedules at G.S. 90-89 to 90-94 (codes.findlaw.com)
Human growth hormone under state law: Not separately scheduled; the federal statute 21 U.S.C. § 333(e) applies (N.C. Gen. Stat. 90-91 (Schedule III)) (codes.findlaw.com)
Research peptides scheduled by the state: Chorionic gonadotropin (hCG), Schedule III (N.C. Gen. Stat. 90-91(k), item 7 of the anabolic steroid list, excepting veterinary use) (codes.findlaw.com)
Board of Pharmacy on compounded GLP-1s: The Board of Pharmacy's July 2023 newsletter (item 2465) applied the federal essentially-a-copy rules to compounding semaglutide, taking the position that only semaglutide base is a component of an FDA-approved drug and that salt forms such as semaglutide sodium and semaglutide acetate are research-use-only substances not appropriate for compounding. The Board's PDF blocks automated fetches, so the salt-form wording is confirmed through law-firm summaries of it (2023-07) (ncbop.org)
Medical board on peptide prescribing: No statement located
GLP-1 by telehealth: Yes. The Medical Board's position statement on telemedicine (last amended March 2024) says the pre-prescribing evaluation need not be in person if the technology meets the standard of care, but that diagnosing or prescribing based solely on static online questionnaires is not acceptable; questionnaires must allow follow-up questions. GLP-1s are non-controlled, so a video or equivalent telehealth visit suffices. (ncmedboard.org)
State-level enforcement, 2023 to 2026: 1 action found
Last verified: 28 September 2026, confidence medium

The federal rules that apply in North Carolina, as everywhere

Federal law is the same in every state, and it is where almost all of the legal weight sits. Under the Federal Food, Drug, and Cosmetic Act a product intended to treat a condition or change how the body works is a drug, and an unapproved new drug cannot be introduced into interstate commerce. That rule binds the seller, not the buyer. The FDA's 2026 warning letters to research-peptide vendors say the same thing eleven times over: a "research use only" label does not help when the website, the bundled bacteriostatic water or a dosing calculator shows the product is meant for human use. The Bureau's enforcement tracker lists every letter, case and lawsuit with its source.

Three federal points matter for a reader in North Carolina:

Human growth hormone is the exception. 21 U.S.C. § 333(e) makes it a federal offence to distribute or possess somatropin for any use not approved by the Secretary of HHS. That statute covers HGH itself, not the secretagogues (sermorelin, ipamorelin, CJC-1295) that prompt the body's own release.
Compounding is a separate track. A licensed pharmacy may only compound from bulk substances on the FDA's 503A list. BPC-157, TB-500, MOTS-c, KPV, Semax and Epitalon were moved to Category 2 in September 2023, removed from it in April 2026, and recommended for the list by the FDA's advisory committee on 23 and 24 July 2026. No rule has followed as of September 2026, so they still cannot be legally compounded anywhere, including North Carolina. The PCAC vote page has every tally.
GLP-1 compounding is closing, not opening. The FDA has declared the semaglutide and tirzepatide shortages over, proposed in April 2026 to keep both off the 503B bulks list, and sent batches of letters to telehealth sellers in March and June 2026. Vials sold as "GLP-1 S" or "GLP-3 R" for research are unapproved new drugs in the FDA's view wherever the buyer lives.

What North Carolina law adds

North Carolina's controlled-substances law (North Carolina Controlled Substances Act, N.C. Gen. Stat. Chapter 90, Article 5, Sections 90-86 et seq.; schedules at G.S. 90-89 to 90-94) decides whether possessing a compound is a state offence. Peptides only become a state-law problem if they appear in those schedules or in a specific state ban. (codes.findlaw.com)

Compounds North Carolina has scheduled or restricted

Chorionic gonadotropin (hCG), Schedule III (N.C. Gen. Stat. 90-91(k), item 7 of the anabolic steroid list, excepting veterinary use) (codes.findlaw.com)

Human growth hormone

Human growth hormone and somatropin are not listed in North Carolina's Schedule III or elsewhere in the state schedules; only chorionic gonadotropin is swept into the anabolic steroid subdivision. HGH is prescription-only in North Carolina with no state restriction beyond federal law. (N.C. Gen. Stat. 90-91 (Schedule III)) (codes.findlaw.com)

Compounded semaglutide and tirzepatide

2023-07. The Board of Pharmacy's July 2023 newsletter (item 2465) applied the federal essentially-a-copy rules to compounding semaglutide, taking the position that only semaglutide base is a component of an FDA-approved drug and that salt forms such as semaglutide sodium and semaglutide acetate are research-use-only substances not appropriate for compounding. The Board's PDF blocks automated fetches, so the salt-form wording is confirmed through law-firm summaries of it. (ncbop.org)

This is about licensed pharmacies and prescriptions. It does not make a research vial legal or illegal; those sit under the federal unapproved-drug rules described above.

Clinics, medspas and prescribers

No North Carolina medical board guidance specific to peptide therapy was located. A North Carolina prescriber who administers BPC-157 or another unapproved peptide is exposed under the state's medical practice act and, since the FDA's 2026 letters, under federal law; the July 2026 advisory vote has not changed that yet.

Buying, possessing and using research peptides in North Carolina

G.S. 90-95(a)(3) criminalises possession of a controlled substance only, so possessing an unscheduled research peptide is not a state drug offence; hCG is Schedule III in North Carolina and possessing it without a prescription is one. No general North Carolina offence for possessing a non-controlled prescription drug was identified. (codes.findlaw.com)

Ordering from a vendor in another state. Almost every research-peptide order into North Carolina is interstate commerce, which is exactly what the FDCA governs. The risk sits with the vendor: the FDA's letters name the seller, and Eli Lilly said in August 2026 it had referred more than 200 sellers to the FDA, the DOJ, state attorneys general and licensing boards. Connecticut's attorney general has already used state consumer-protection law against a "research grade" GLP-1 seller (2025), which is the template other states can copy. The Bureau's vendor scorecard notes which vendors publish batch testing; none of the scored vendors appears in the tracker as of September 2026.

GLP-1 drugs by prescription. Yes. The Medical Board's position statement on telemedicine (last amended March 2024) says the pre-prescribing evaluation need not be in person if the technology meets the standard of care, but that diagnosing or prescribing based solely on static online questionnaires is not acceptable; questionnaires must allow follow-up questions. GLP-1s are non-controlled, so a video or equivalent telehealth visit suffices. (ncmedboard.org) The branded pens are the only fully approved route; compounded versions are now on the wrong side of the FDA's shortage rules.

Sports and employment testing are not a North Carolina law question. Growth hormone secretagogues and GHRH analogues are on the WADA Prohibited List everywhere; a standard workplace panel does not screen for peptides. The national legal guide covers both.

Not sure which of these you actually need?

Answer five questions about your goal, experience and budget and the Stack Builder shows you a matched research protocol on screen, with the compounds, cycle shape and vendor picks from the vendors we score.

Build your stack, 2 minutes

Enforcement in North Carolina

2025-02-19. North Carolina's attorney general signed the 38-state letter urging the FDA to act against counterfeit and research-only GLP-1 sales. (naag.org)

A warning letter, lawsuit or board complaint is an allegation by the body that issued it, not a court finding, unless the entry says otherwise.

Editor's note. An editor should open the Board of Pharmacy's July 2023 PDF directly before quoting its salt-form wording. No Medical Board statement on research peptides, BPC-157 or peptide clinics was found.

Frequently asked questions

Is BPC-157 legal in North Carolina?

North Carolina has not scheduled BPC-157, so possessing it is not a North Carolina offence. Federally it is an unapproved new drug: selling it for human use is a violation by the seller, and licensed pharmacies cannot compound it because it is not on the 503A bulks list, despite the advisory committee's July 2026 recommendation. Research vendors sell it under a research-use-only label, which the FDA's 2026 letters treat as no defence when the site shows human use.

Can I get semaglutide or tirzepatide by telehealth in North Carolina?

Yes. The Medical Board's position statement on telemedicine (last amended March 2024) says the pre-prescribing evaluation need not be in person if the technology meets the standard of care, but that diagnosing or prescribing based solely on static online questionnaires is not acceptable; questionnaires must allow follow-up questions. GLP-1s are non-controlled, so a video or equivalent telehealth visit suffices. The North Carolina Board of Pharmacy position on compounded versions: The Board of Pharmacy's July 2023 newsletter (item 2465) applied the federal essentially-a-copy rules to compounding semaglutide, taking the position that only semaglutide base is a component of an FDA-approved drug and that salt forms such as semaglutide sodium and semaglutide acetate are research-use-only substances not appropriate for compounding. The Board's PDF blocks automated fetches, so the salt-form wording is confirmed through law-firm summaries of it.

Is HGH legal in North Carolina?

Only with a valid prescription for an approved use. North Carolina does not schedule it separately, but federal law, 21 U.S.C. section 333(e), makes distribution or possession for any non-approved use a federal offence. Sermorelin, ipamorelin and CJC-1295 are not HGH and fall under the general unapproved-drug rules instead.

Sources

Every North Carolina fact above was checked against the linked source on 28 September 2026. If a statute or board position has changed, email [email protected] with the link and the page will be corrected and dated.